在英国的一次试验中,正在对多达80名ALS病人进行针对神经发炎的Nflamapimod的测试。 Neflamapimod, targeting neuroinflammation, is being tested in up to 80 ALS patients in a UK trial.

CervoMed的药物neflamapimod已被选入英国专家-ALS试验平台,这是一个治疗ALS的快速评估倡议。 CervoMed's drug neflamapimod has been selected for the UK’s EXPERTS-ALS trial platform, a rapid evaluation initiative for ALS treatments. 该药物通过抑制P38MAP动脉酶,针对神经刺激,将在18至24周内对多达80名患者进行检测,测量神经纤维链光链的变化和临床结果。 The drug, which targets neuroinflammation by inhibiting p38 MAP kinase, will be tested in up to 80 patients over 18 to 24 weeks, measuring changes in neurofilament light chain and clinical outcomes. 该平台在联合王国卫生机构和慈善机构的支持下,利用多臂设计来加速评估有前途的疗法。 The platform, backed by UK health agencies and charities, uses a multi-arm design to accelerate assessment of promising therapies. Neflamapimido的融入遵循了支持性临床前和前临床数据。 Neflamapimod’s inclusion follows supportive preclinical and prior clinical data. 该公司计划于2026年晚些时候与Lewy机构进行第3阶段痴呆症试验,等待资金到位。 The company plans a Phase 3 trial in dementia with Lewy bodies later in 2026, pending funding.